President Trump's latest executive order modifies the Medicare Drug Price Negotiation Program, aligning the treatment of small molecule drugs with biologics and aiming to reduce drug prices.

President Trump signed an executive order to lower Medicare drug prices by enhancing drug price negotiations, increasing market transparency, and targeting anti-competitive behaviors.

U.S. Representatives urge a probe into Medicare Advantage plans acquiring health businesses, potentially affecting compliance with medical loss ratio standards.

Explore the key findings from the Peterson Center on Healthcare's latest report on Remote Patient Monitoring (RPM) and Remote Therapeutic Monitoring (RTM), suggesting essential reforms for Medicare.

Explore significant updates in the U.S. insurance industry related to prior authorization, including federal and state legislative shifts, and the deployment of AI technology.

In upstate New York, Medicare Advantage plan beneficiaries face possible cuts in benefits and increases in costs due to changes in the Medicare wage index. Learn about the legislative efforts to mitigate this issue.

Discover the latest changes in Medicare Advantage policies announced by CMS for 2026, highlighting new compliance standards and efforts to improve healthcare integration and quality.

Cobi Blumenfeld-Gantz testified before the Senate Finance Committee, discussing misleading marketing practices in Medicare Advantage plans, spotlighting the need for stricter regulatory oversight.

Pathlight Capital becomes the Administrative Agent for a $210M credit facility for Spring Venture Group, enhancing its position in the Medicare brokerage sector.

Explore recent U.S. Medicare policy changes including Trump's executive orders to lower healthcare costs and legislative advocacy to cover anti-obesity drugs, alongside market developments involving Humana and Cone Health.